“The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.”
All entries for: Oncology
August 9, 2023
Adicet Bio
Negative Outlook
Boston, MA
51-200 employees
51-200 employees
Disease Area: Oncology
Drug Type: Biologic
August 9, 2023
Pfizer
Neutral Outlook
New York, NY
50,001+ employees
50001+ employees
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
August 9, 2023
Context Therapeutics
Negative Outlook
Philadelphia, PA
1-50 employees
1-50 employees
Disease Area: Oncology
Drug Type: Biologic
August 8, 2023
Recursion Pharmaceuticals
Neutral Outlook
Salt Lake City, UT
201-500 employees
201-500 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
August 8, 2023
Halozyme Therapeutics
Negative Outlook
San Diego, CA
201-500 employees
201-500 employees
Disease Area: Oncology
Drug Type: Biologic
August 8, 2023
Eli Lilly & Company
Negative Outlook
Indianapolis, IN
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic
August 8, 2023
CytomX Therapeutics
Negative Outlook
San Francisco, CA
51-200 employees
51-200 employees
Disease Area: Oncology
Drug Type: Biologic
August 7, 2023
AbbVie
Negative Outlook
Chicago, IL
50,001+ employees
50001+ employees
Disease Area: Oncology
Drug Type: Biologic
August 7, 2023
Merck
Negative Outlook
Rahway, NJ
50,001+ employees
50001+ employees
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
August 3, 2023
IGM Biosciences
Negative Outlook
Mountain View, CA
201-500 employees
201-500 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
